医学
内科学
肾脏疾病
糖尿病
重症监护医学
内分泌学
疾病
作者
Nayana Khurana,Steven James,Melinda T. Coughlan,Richard J. MacIsaac,Elif I. Ekinci
标识
DOI:10.1210/clinem/dgab639
摘要
Trials have yielded promising results in the search for new therapies to manage DKD. SGLT2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid receptor antagonists are another class of agents with increasing evidence of benefits.
科研通智能强力驱动
Strongly Powered by AbleSci AI